Search Results

Amyris, Inc. announced financial results for the first quarter ended March 31, 2023.

Amyris, Inc. announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

Amyris, Inc. announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately.

Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.

Amyris, Inc. announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris’ ingredients.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Near-term applications include combinations with kinase inhibitors (KIs) that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location

Amyris, Inc., a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, provided an update on first quarter revenue.

Amyris, Inc. announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers and established a subcommittee of the Board, made up of three independent directors, working with Management, to execute on a transformation program to accelerate improvements to the Company’s cost and capital structure and liquidity.